UC Berkeley's genetic drug developer 4DMT has pulled away from a proposed $100m offering after closing series C funding last month.

4D Molecular Therapeutics (4DMT), the US-based gene therapy spinout of University of California, Berkeley and backed by its Berkeley Catalyst Fund, withdrew its application for an initial public offering on Tuesday. Founded in 2013, 4DMT is working on adeno-associated virus-based treatments for a genetic disorder known as Fabry disease, in addition to retinal conditions retinitis…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.